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VAlprOATE-INDuCED gINgIVAl OVErgrOWTH : A CASE rEpOrT
Jihyeo Song, Koeun lee, minkyung Shin, Seong-Oh Kim, byungjai Choi, Hyung-Jun Choi*
Department of Pediatric Dentistry, College of Dentistry, Yonsei University  
Drug-induced gingival overgrowth is an abnormal increase of  gingival tissues caused as a side effect of  systemic 
medication.
This report presents a severe case of  valproate-induced gingival overgrowth combined with ulcerative and hemorrhagic 
lesions in a patient with Lennox-Gastaut syndrome. Considering the patient’s limited cooperative ability, gingivectomy and 
excisional biopsy under general anesthesia were performed. The lesions were successfully treated without recurrence.
When gingival enlargement does not subside with nonsurgical treatments, surgical procedure and excisional biopsy are 
to be performed. Postoperative management of  oral hygiene is critical to prevent recurrence. [J Korean Dis Oral Health 
Vol.14, No.2: 92-96, December 2018]
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Abstract
Ⅰ.	Introduction
Gingival overgrowth, also known as gingival enlargement or 
gingival hyperplasia, is an abnormal increase of  gingival tissues. 
Gingival overgrowth can be caused by several factors; (1) inflam-
matory gingival enlargement, (2) medication-induced gingival en-
largement, (3) hereditary gingival fibromatosis, and (4) systemic 
causes of  gingival enlargement1). The treatment depends on the 
underlying cause.
Drug-induced gingival overgrowth occurs in whole or in part 
from systemic medication. It occurs as a side effect following 
systemic drug use for non-dental treatments: phenytoin, an an-
tiepileptic; cyclosporine A, an immunosuppressant; and calcium 
channel blockers such as nifedipine, verapamil, and amlodipine 
for cardiovascular diseases. These drugs cause critical changes in 
fibroblast function, which result in an increase in the extracellular 
matrix of  the gingival connective tissue2).
Drug-induced gingival overgrowth generally initiates on in-
terdental gingival papillae in anterior teeth, usually within two 
or three months after initiation of  medication. The severity of  
gingival enlargement may be related to the dose, duration, and 
plasma levels of  the drug, but some studies argue against this 
concept. Many studies have reported a significant correlation 
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between the level of  plaque and calculus accumulation and the 
severity of  gingival overgrowth3,4).
Although the side effect of  phenytoin on gingival overgrowth 
is widely known, other anticonvulsant drugs such as barbiturate, 
valproic acid, succinimides, and carbamazepine have been rarely 
reported to induce gingival overgrowth3-5). The incidence of  gin-
gival overgrowth caused by these drugs is low compared to that 
of  phenytoin-induced gingival overgrowth.
This report presents a severe case of  valproate-induced gin-
gival overgrowth combined with ulcerative and hemorrhagic 
lesions that occurred in all four quadrants in a patient with Len-
nox-Gastaut syndrome.
Ⅱ.	Case Report
A 7-year-3-month-old male patient visited Department of  
Pediatric Dentistry, Yonsei University Dental Hospital with the 
chief  complaint of  enlargement of  gingiva and bleeding. The pa-
tient was known to have had Lennox-Gastaut syndrome and was 
on medication since last seven years; valproic acid, rufinamide, le-
vetiracetam, and phenobarbital. He had severe mental retardation 
showing developmental age of  three months. He had a medical 
history of  infantile spasms.
On intraoral examination, overgrown gingival tissue was ob-
served on mandibular left molar area measuring approximately 
2.0 × 2.0 × 1.0 cm. Fully erupted mandibular left first molar was 
covered with overgrown soft tissue and unseen, and mandibular 
left deciduous second molar was also partially covered with over-
lying soft tissue. The soft tissue mass overlying was erythematous 
and ulcerative in appearance and showed spontaneous bleeding 
(Fig. 1A). The enlarged gingival tissue had dark red color showing 
hematomatic changes. The patient exhibited poor oral hygiene. 
Radiographic examination revealed no abnormalities (Fig. 1B). 
Based on patient’s history, clinical evaluation and radiographic 
assessment, a provisional diagnosis of  valproic acid-induced 
gingival overgrowth superimposed with inflammation was estab-
lished.
Irrigation with 10 mL of  0.2% chlorhexidine and saline was 
performed. The parents were instructed to improve the oral 
hygiene of  the patient and to revisit clinic two days later for fol-
low-up. On his second visit, however, the lesion on mandibular 
left area did not subside at all and the gingiva on maxillary left 
molar area showed mild gingival swelling and bleeding tendency. 
The enlarged gingival tissue was irrigated with chlorhexidine and 
saline, and an oral antibiotic was prescribed for five days. The 
parents were educated to rinse the lesion with 10 mL of  0.2% 
chlorhexidine mouthwash and saline twice daily and to maintain 
strict oral hygiene. He was asked to report back after one week. 
The tissue in the meantime, however, did not decrease in size 
and inflammation did not subside. One week after his second 
visit, the involved teeth, mandibular left deciduous canine, first 
molar, second molar, showed increased mobility and the affected 
areas were expanded to the maxillary right side. Considering the 
patient’s limited cooperative ability, gingivectomy under general 
anesthesia was planned.
Surgical procedure was performed under general anesthesia 
with respect to four quadrants to remove the overgrowing tissue 
using surgical blades (Fig. 2). Fibrous bony lesion was detected 
on the alveolar bone on mandibular left first molar area and fa-
cial swelling was observed on mandibular angle area of  the same 
side. Alveolar curettage and drain insertion was done to eliminate 
all pathological material. The wound was closed with 4-0 sutures.
The tissues excised were fixed in 10% formalin and sent for 
histological assessment, which revealed an increase in connective 
tissue and a relative decrease in epithelial thickness. Inflamma-
tory cell infiltration was found in a mixture of  dense and loose 
fibrous connective tissue with extensive hemorrhage and edema 
(Fig. 3). This confirmed our diagnosis of  drug associated gingival 
enlargement. The bone fragments showed mature cancellous 
bone with fibrous stroma. Patient was asked to come for check-
Fig. 1. (A) Intraoral photograph and (B) Periapical 
radiograph taken on the patient’s first visit to 
the clinic. Gingival overgrowth is observed on 
mandibular left molar area.
A B
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up after two weeks. Patient was also prescribed anti-inflamma-
tory analgesic drug for management of  postoperative pain for 
five days. Patient was asked to maintain oral hygiene strictly in 
the surgically treated area, as the treated area was open and raw 
wound surface.
On examination after two weeks, the overgrowth had subsided 
almost completely. No further surgical treatment was planned but 
patient was asked to maintain strict oral hygiene. On examination 
after six weeks, the mobility of  mandibular left teeth entirely 
disappeared and good oral health was established. The patient 




Fig. 2. (A-C) Preoperative intraoral photographs and (D-F) Postoperative intraoral photographs taken in operating room. (A) and (D) 
show the maxillary right quadrant. (B) and (E) show the mandibular left quadrant. (C) and (F) show the mandibular right quadrant.
A B
C D
Fig. 3. (A-C) Histopathological examination 
of gingival overgrowth. (A) Low-power 
view showing excess fibrous connective 
tissue and hemorrhage (H-E, X40). (B) 
Excessive fibrous connective tissue (H-
E, X100). (C) Extensive hemorrhage (H-
E, X100). (D) Mature cancellous bone with 
fibrous stroma (H-E, X100).
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Ⅲ.	Discussion
The patient described herein had Lennox-Gastaut syndrome, 
which is an intractable form of  childhood-onset epilepsy. The 
syndrome is characterized by a triad of  signs including multiple 
types of  epileptic seizures to include tonic, atypical absences, 
and drop attacks, an interictal EEG showing generalized slow 
spike wave (1.5 to 2.5 Hz) during awake and paroxysmal fast ac-
tivity (PFA) during sleep, and slow mental development and/or 
behavior disturbance.6) The present patient was taking multiple 
antiepileptic drugs (AEDs), DepaKOTE (valproate), Inovelon 
(rufinamide), Keppra (levetiracetam) and phenobarbital, to main-
tain seizure freedom.
AEDs are widely known to have the potential to cause gingival 
overgrowth as one of  the adverse effects. The prevalence of  
gingival overgrowth has been shown to vary, from 13 to 50%, in 
the patients on long-term phenytoin medication7). Bharat et al.8) 
reported that phenytoin caused gingival overgrowth in 53.6% of  
children within three months.
Drug-induced gingival overgrowth begins as a firm, nodular 
enlargement of  the interdental papilla, limited to keratinized por-
tions of  the gingiva. Fibroblasts in the connective tissue are the 
target cells. Inflammatory microenvironment is a prerequisite for 
development of  overgrowth because fibroblasts are in an active 
state when the tissue is inflamed. Local stimuli on the overgrown 
gingiva bring about inflammatory changes turning the affected 
area into dark red-colored and easy-to-bleed tissue.
The mechanism of  pathogenesis of  gingival overgrowth has 
not been thoroughly disclosed. The associated drugs affect cel-
lular calcium metabolism and calcium influx modulates cellular 
production of  collagenase. Fibroblasts in the patients medicated 
with these drugs may produce an inactive form of  collagenase, 
which cause an increase in extracellular matrix2). Kato et al.9) 
suggested that TNF-α and phenytoin together cause impairment 
in collagen metabolism by suppression of  enzymatic degrada-
tion with MMPs/TIMP-1 and integrin-mediated endocytosis. 
Recent studies report that gingival overgrowth is induced by the 
disruption of  homeostasis in collagen synthesis and degradation 
of  gingival connective tissue, primarily due to the inhibition of  
collagen phagocytosis of  gingival fibroblasts4).
The patient herein was taking valproic acid, which is used to 
treat seizure disorders and certain psychiatric conditions (e.g., 
manic phase of  bipolar disorder, schizophrenia) and prevent 
migraine headaches. The pharmacodynamics of  the agent is not 
clearly known, but it is supposed to have anticonvulsant effects 
associated with increased gamma-aminobutyric acid (GABA) in 
brain.
To our knowledge, there have been only a few case reports in 
the literature concerning valproate-induced gingival enlargement. 
A case of  gingival overgrowth occurred in a 14-year-old girl, 
eighteen months after the taking valproate, was reported by Be-
hari10). Joshipura11) reported an unusual case in which the patient 
not having any gingival problem in spite of  taking phenytoin 
for one year developed gingival overgrowth after taking sodium 
valproate within six months. Banita et al.12) reported a case of  a 
neonate with fetal valproate syndrome.
Histologic examination revealed increased volume of  fibrotic 
connective tissue. According to Kataoka et al.13,14), drug-induced 
gingival overgrowth is shown to be induced by the excessive ac-
cumulation of  type I collagen in connective tissue in rats.
Abundant red blood cells and inflammatory cells were ob-
served in gingival connective tissue and intermittent discontinua-
tion of  epithelium was seen. It is thought that the increased vol-
ume of  soft tissue has interfered with the occlusion of  deciduous 
molars on the affected side and continuous stimuli by maxillary 
teeth have made the lesion worse resulting in ulceration, hemor-
rhage and inflammatory changes.
The ideal treatment for medically induced gingival enlargement 
is discontinuation of  medication. This approach, however, is of-
ten impractical. Reducing polytherapy and employing monother-
apy with lowest effective dose may contribute to avoid and min-
imize drug-induced gingival overgrowth7). Definitive treatment 
is surgical removal of  excess gingival tissue, especially in patients 
with severe gingival overgrowth that compromise esthetics and 
function. The use of  carbon dioxide laser surgery is becoming 
common in gingivectomy due to advantages in postoperative 
hemostasis15). Although an operation provides immediate and 
dramatic results, gingival overgrowth has the potential to recur 
when the causative medication must be used for ongoing therapy. 
In some patients, periodic surgical reduction of  soft tissue is nec-
essary and good oral hygiene can decrease or prevent the gingival 
overgrowth16).
Ⅳ.	summary
Drug-induced gingival overgrowth is an unusual gingival 
enlargement which is caused by unwanted effects of  systemic 
medication. In the case described herein, valproate-induced 
gingival overgrowth occurred in all four quadrants exhibiting 
ulcerated and hemorrhagic manifestations in a patient with Len-
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nox-Gastaut syndrome. When gingival enlargement does not 
subside with nonsurgical treatments, surgical procedure is to be 
performed. Postoperative management of  oral hygiene is critical 
to prevent recurrence.
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